RET kinase inhibitors: a review of recent patents (2012–2015)

References

• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985;42(2):581–588.
   PubMed Web of Science ®Google Scholar
• Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–1113.
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18(3):382–384.
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012;18(3):375–377.
   PubMed Web of Science ®Google Scholar
• Borrello MG, Ardini E, Locati LD, et al. RET inhibition: implications in cancer therapy. Expert Opin Ther Targets. 2013;17(4):403–419.
   PubMed Web of Science ®Google Scholar
• Le Rolle A-F, Klempner SJ, Garrett CR, et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget. 2015;6(30):28929–28937.
   PubMed Web of Science ®Google Scholar
• Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem. 2011;18(2):162–175.
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4–5):441–467.
   PubMed Web of Science ®Google Scholar
• Lanzi C, Cassinelli G, Nicolini V, et al. Targeting RET for thyroid cancer therapy. Biochem Pharmacol. 2009;77(3):297–309.
   PubMed Web of Science ®Google Scholar
• Plaza-Menacho I, Mologni L, McDonald NQ. Mechanisms of RET signaling in cancer: current and future implications for targeted therapy. Cell Signal. 2014;26(8):1743–1752.
   PubMed Web of Science ®Google Scholar
• Mologni L, Redaelli S, Morandi A, et al. Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013;377(1–2):1–6.
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Satoh Y, et al. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther. 2014;13(12):2910–2918.
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91(10):4070–4076. Epub 2006 Jul 18.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96(2):E288–E296.
   PubMed Web of Science ®Google Scholar
• Mologni L, Sala E, Cazzaniga S, et al. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006;37(2):199–212.
   PubMed Web of Science ®Google Scholar
• Mologni L, Rostagno R, Brussolo S, et al. Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010;18(4):1482–1496.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98(5):326–334.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002;62(24):7284–7290.
   PubMed Web of Science ®Google Scholar
• Cohen MS, Hussain HB, Moley JF. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery. 2002;132(6):960–966; discussion 966–967.
   PubMed Web of Science ®Google Scholar
• Lanzi C, Cassinelli G, Pensa T, et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer. 2000;85(3):384–390.
   PubMed Web of Science ®Google Scholar
• Strock CJ, Park J-I, Rosen M, et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003;63(17):5559–5563.
   PubMed Web of Science ®Google Scholar
• Knowles PP, Murray-Rust J, Kjaer S, et al. Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem. 2006;23:23.
   Google Scholar
• Wells SA Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134–141.
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646.
   PubMed Web of Science ®Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660–2666.
   PubMed Web of Science ®Google Scholar
• Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630–635.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Plaza-Menacho I, Mologni L, Sala E, et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007;282(40):29230–29240.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer. 2015;121(16):2749–2756.
   PubMed Web of Science ®Google Scholar
• Song M. Progress in discovery of KIF5B-RET kinase inhibitors for the treatment of non-small-cell lung cancer. J Med Chem. 2015;58(9):3672–3681.
   PubMed Web of Science ®Google Scholar
• Dadu R, Hu MN, Grubbs EG, et al. Use of tyrosine kinase inhibitors for treatment of medullary thyroid carcinoma. Recent Results Cancer Res. 2015;204:227–249.
   PubMedGoogle Scholar
• Phay JE, Shah MH. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010;16(24):5936–5941.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Drugs. 2014;74(12):1435–1444.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Di Bari F, Ferrari SM, et al. Selective use of vandetanib in the treatment of thyroid cancer. Drug Des Devel Ther. 2015;9:3459–3470.
   PubMed Web of Science ®Google Scholar
• Aftab DT Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma. WO2014039971. 2014.
   Google Scholar
• Bannen LC C-met modulators and methods of use. WO2005030140. 2005.
   Google Scholar
• St CBA. Malate salt of n- (4- {[6, 7-bis (methyloxy) quinolin-4-yl] oxy}phenyl-n’ -(4 -fluorophenyl) cyclopropane-1-dicarboxamide, and crystalline forms thereof for the treatment of cancer. WO2010083414. 2010.
   Google Scholar
• Burns CJ Inhibitors of kinase activity. US20130137660 /US9029386. 2013.
   Google Scholar
• Eidam HS. Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors. WO2014141187 /US9382238. 2014.
   Google Scholar
• Angiolini M Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors. WO2014184069. 2014.
   Google Scholar
• Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene. 2004;23(36):6056–6063.
   PubMed Web of Science ®Google Scholar
• Zhou T, Commodore L, Huang W-S, et al. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2011;77(1):1–11.
   PubMed Web of Science ®Google Scholar
• Menichincheri M Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors. WO2014072220. 2014.
   Google Scholar
• Dar AC, Das TK, Sos ML, et al. Substituted pyrazolo[3,4-D]pyrimidines and uses thereof. WO2013077921 /US9321772. 2013.
   Google Scholar
• Dar AC, Das TK, Shokat KM, et al. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature. 2012;486(7401):80–84.
   PubMed Web of Science ®Google Scholar
• Sim TB Novel indazole derivatives or pharmaceutically acceptable salts thereof as protein kinase inhibitors for proliferative diseases treatment, and a pharmaceutical composition containing the same as an active ingredient. US20120130069 /US8754209. 2012.
   Google Scholar
• Kodama T Ret inhibitor. US20140272958 /WO2014050781. 2015.
   Google Scholar
• Shimada I Arylaminoheterocyclic carboxamide compound. WO2012053606. 2012.
   Google Scholar
• Goldberg K. Quinazoline compounds. WO2015079251. 2015.
   Google Scholar
• Arai T Preventives/remedies for cancer. US20120231001 /WO2007049624. 2012.
   Google Scholar
• Esseghir S, Todd SK, Hunt T, et al. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Research. 2007;67(24):11732–11741.
   PubMed Web of Science ®Google Scholar
• Alamgeer M, Ganju V, Watkins DN. Novel therapeutic targets in non-small cell lung cancer. Curr Opin Pharmacol. 2013;13(3):394–401.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–566.
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12 Pt 1):3314–3322.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12):3123–3127.
   PubMed Web of Science ®Google Scholar